![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![AbbVie](https://www.pharmacompass.com/image/flap/abbvie-corp-adgif-27965.gif)
![AbbVie](https://www.pharmacompass.com/image/flap/abbvie-corp-ad-w33-mob-headergif-39012.gif)
Active Filter(s):
Details:
The series A financing will help in accelerating Medilink's innovative pipeline development and to support its unique conjugate technology platform.
Lead Product(s): Antibody-drug conjugate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Apricot Capital
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing March 01, 2021